43 related articles for article (PubMed ID: 17301844)
1. Engineering the
Sharrock AV; McManaway SP; Rich MH; Mumm JS; Hermans IF; Tercel M; Pruijn FB; Ackerley DF
Front Pharmacol; 2021; 12():701456. PubMed ID: 34163368
[TBL] [Abstract][Full Text] [Related]
2. Optimized clostridium-directed enzyme prodrug therapy improves the antitumor activity of the novel DNA cross-linking agent PR-104.
Liu SC; Ahn GO; Kioi M; Dorie MJ; Patterson AV; Brown JM
Cancer Res; 2008 Oct; 68(19):7995-8003. PubMed ID: 18829557
[TBL] [Abstract][Full Text] [Related]
3. Design and synthesis of bioreductive prodrugs of class I histone deacetylase inhibitors and their biological evaluation in virally transfected acute myeloid leukemia cells.
Abdelsalam M; Zmyslia M; Schmidtkunz K; Vecchio A; Hilscher S; Ibrahim HS; Schutkowski M; Jung M; Jessen-Trefzer C; Sippl W
Arch Pharm (Weinheim); 2024 Feb; 357(2):e2300536. PubMed ID: 37932028
[TBL] [Abstract][Full Text] [Related]
4. Cell-Penetrating Peptides as a Tool for the Cellular Uptake of a Genetically Modified Nitroreductase for use in Directed Enzyme Prodrug Therapy.
Anderson SD; Hobbs RJ; Gwenin VV; Ball P; Bennie LA; Coulter JA; Gwenin CD
J Funct Biomater; 2019 Oct; 10(4):. PubMed ID: 31581475
[TBL] [Abstract][Full Text] [Related]
5. Site-Specific Antimicrobial Activity of a Dual-Responsive Ciprofloxacin Prodrug.
Ross CL; Lawer A; Sircombe KJ; Pletzer D; Gamble AB; Hook S
J Med Chem; 2024 May; ():. PubMed ID: 38780408
[TBL] [Abstract][Full Text] [Related]
6. A metagenomic library cloning strategy that promotes high-level expression of captured genes to enable efficient functional screening.
Rich MH; Sharrock AV; Mulligan TS; Matthews F; Brown AS; Lee-Harwood HR; Williams EM; Copp JN; Little RF; Francis JJ; Horvat CN; Stevenson LJ; Owen JG; Saxena MT; Mumm JS; Ackerley DF
bioRxiv; 2023 Mar; ():. PubMed ID: 36993673
[TBL] [Abstract][Full Text] [Related]
7. Nitroreductase-mediated cell/tissue ablation in zebrafish: a spatially and temporally controlled ablation method with applications in developmental and regeneration studies.
Curado S; Stainier DY; Anderson RM
Nat Protoc; 2008; 3(6):948-54. PubMed ID: 18536643
[TBL] [Abstract][Full Text] [Related]
8. Structure and Dynamics of Three
Day MA; Christofferson AJ; Anderson JLR; Vass SO; Evans A; Searle PF; White SA; Hyde EI
Int J Mol Sci; 2023 Mar; 24(6):. PubMed ID: 36983061
[No Abstract] [Full Text] [Related]
9. NTR 2.0: a rationally engineered prodrug-converting enzyme with substantially enhanced efficacy for targeted cell ablation.
Sharrock AV; Mulligan TS; Hall KR; Williams EM; White DT; Zhang L; Emmerich K; Matthews F; Nimmagadda S; Washington S; Le KD; Meir-Levi D; Cox OL; Saxena MT; Calof AL; Lopez-Burks ME; Lander AD; Ding D; Ji H; Ackerley DF; Mumm JS
Nat Methods; 2022 Feb; 19(2):205-215. PubMed ID: 35132245
[TBL] [Abstract][Full Text] [Related]
10. Enhanced cell-specific ablation in zebrafish using a triple mutant of Escherichia coli nitroreductase.
Mathias JR; Zhang Z; Saxena MT; Mumm JS
Zebrafish; 2014 Apr; 11(2):85-97. PubMed ID: 24428354
[TBL] [Abstract][Full Text] [Related]
11. A mammalianized synthetic nitroreductase gene for high-level expression.
Grohmann M; Paulmann N; Fleischhauer S; Vowinckel J; Priller J; Walther DJ
BMC Cancer; 2009 Aug; 9():301. PubMed ID: 19712451
[TBL] [Abstract][Full Text] [Related]
12. E. coli NfsA: an alternative nitroreductase for prodrug activation gene therapy in combination with CB1954.
Vass SO; Jarrom D; Wilson WR; Hyde EI; Searle PF
Br J Cancer; 2009 Jun; 100(12):1903-11. PubMed ID: 19455141
[TBL] [Abstract][Full Text] [Related]
13. Direct positive selection for improved nitroreductase variants using SOS triggering of bacteriophage lambda lytic cycle.
Guise CP; Grove JI; Hyde EI; Searle PF
Gene Ther; 2007 Apr; 14(8):690-8. PubMed ID: 17301844
[TBL] [Abstract][Full Text] [Related]
14. Discovery and evaluation of Escherichia coli nitroreductases that activate the anti-cancer prodrug CB1954.
Prosser GA; Copp JN; Syddall SP; Williams EM; Smaill JB; Wilson WR; Patterson AV; Ackerley DF
Biochem Pharmacol; 2010 Mar; 79(5):678-87. PubMed ID: 19852945
[TBL] [Abstract][Full Text] [Related]
15. Nitroreductase: a prodrug-activating enzyme for cancer gene therapy.
Searle PF; Chen MJ; Hu L; Race PR; Lovering AL; Grove JI; Guise C; Jaberipour M; James ND; Mautner V; Young LS; Kerr DJ; Mountain A; White SA; Hyde EI
Clin Exp Pharmacol Physiol; 2004 Nov; 31(11):811-6. PubMed ID: 15566399
[TBL] [Abstract][Full Text] [Related]
16. Virus-directed enzyme prodrug therapy using CB1954.
Grove JI; Searle PF; Weedon SJ; Green NK; McNeish IA; Kerr DJ
Anticancer Drug Des; 1999 Dec; 14(6):461-72. PubMed ID: 10834268
[TBL] [Abstract][Full Text] [Related]
17. Generation of Escherichia coli nitroreductase mutants conferring improved cell sensitization to the prodrug CB1954.
Grove JI; Lovering AL; Guise C; Race PR; Wrighton CJ; White SA; Hyde EI; Searle PF
Cancer Res; 2003 Sep; 63(17):5532-7. PubMed ID: 14500391
[TBL] [Abstract][Full Text] [Related]
18. Testing double mutants of the enzyme nitroreductase for enhanced cell sensitisation to prodrugs: effects of combining beneficial single mutations.
Jaberipour M; Vass SO; Guise CP; Grove JI; Knox RJ; Hu L; Hyde EI; Searle PF
Biochem Pharmacol; 2010 Jan; 79(2):102-11. PubMed ID: 19665450
[TBL] [Abstract][Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
